NYLIM
TRDA icon

New York Life Investment Management’s Entrada Therapeutics TRDA Stock Holding History

New York Life Investment Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,914
Closed -$367K – 1289
2024
Q1 		$367K Buy
+25,914
New +$366K ﹤0.01% 1048

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

New York Life Investment Management's TRDA Position: Q2 2024 in Review

New York Life Investment Management sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 25,914 shares — an estimated $367K sold.

New York Life Investment Management first reported a position in TRDA in Q1 2024 and held it in 1 quarter. The position peaked at $367K in Q1 2024. 83 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

  • New York Life Investment Management reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 25,914 Entrada Therapeutics shares in Q2 2024, an estimated $367K.
  • New York Life Investment Management first reported a position in Entrada Therapeutics in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Entrada Therapeutics position peaked at $367K in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.